Cart
0

Structural Heart Devices Market by Product (Structural Heart Repair Devices and Replacement Valves), Age Group (Pediatric and Adult), and Indication (Atrial Septal Defect (ASD), Patent Foramen Ovale (PFO), Ventricular Septal Defect (VSD), and Aortic Valve Stenosis) - Global Opportunity Analysis and Industry Forecast, 2014-2022

Get 20% Free Customization In This Report
LI_171768
Pages: 274
Feb 2017 | 2310 Views
 
Author's : Deepa Tatkare
Tables: 74
Charts: 65
 

Structural Heart Devices Market Overview:

Global Structural Heart Devices Market size was valued at $6,006 million in 2015, and is expected to reach $12,076 million by 2022, supported by a CAGR of 10.5% during the forecast period 2016 - 2022. A structural heart disease is a non-coronary defect of the heart, thus not affecting the blood vessels in the heart. Most of the structural heart conditions are present since birth (congenital), but these can also be acquired later in life, owing to wear & tear from infection. Advancements in the medical field have replaced the open heart surgical procedures with minimally invasive procedures, such as transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (TMVR).

Rise in incidence of structural heart diseases (aortic stenosis and mitral regurgitation); technological advancements; development of innovative repair devices, such as annuloplasty rings, occluders; and increase in demand for minimally invasive techniques are factors that drive the structural heart devices market. However, high cost of surgeries and stringent government regulations hamper this growth. Conversely, increase in focus of key players on R&D activities of structural heart devices and upsurge in demand for quick and long-lasting procedures among the geriatric population are expected to provide lucrative opportunities for the players in the structural heart devices market.

STRUCTURAL HEART DEVICES MARKET SEGMENTATION 

Structural Heart Devices Market Segmentation

Get more information on this report : Request Sample Pages

Segment review

According to AMR analysis, the structural heart repair devices segment held nearly half of the global structural heart devices market size in 2015, owing to increase in prevalence of structural heart diseases. In addition, advancements in repair devices and development of innovative products have further fueled the market growth.

STRUCTURAL HEART REPAIR DEVICES MARKET, BY PRODUCT

Structural Heart Repair Devices Market By Product

Get more information on this report : Request Sample Pages

LAMEA structural heart devices industry

Rise in incidence of aortic stenosis coupled with rapid adoption of structural heart devices drives the growth of the structural heart devices market in LAMEA. In addition, increased focus of structural heart devices vendors in emerging markets (such as Asia-Pacific and LAMEA) is set to further contribute to the growth of this market. Lack of healthcare facilities and increased need for treatment devices for structural heart diseases have increased the penetration of major players in the Middle East. Nevertheless, the structural heart devices market growth is driven by improving healthcare infrastructure coupled with rise in disposable income.

Saudi Arabia Structural Heart Devices Industry Overview, 2014-2022 ($Million)

Saudi Arabia Structural Heart Devices Industry Overview

Get more information on this report : Request Sample Pages

Top impacting factors

Rise in number of patients suffering from structural heart diseases

An increase in demand for structural heart devices has been witnessed, owing to the rise in number of patients suffering from structural heart diseases. These disorders are generally congenital; hence, they occur very commonly in a newborn. For instance, as per The Nemours Foundation, about 1 in every 100 newborns suffers from congenital heart defects, which can range from mild to severe. According to Micro Interventional Devices, Inc., in the U.S., about 60 million people, i.e., about 20-25% adult population suffer from structural heart defects. As per the Center for Structural Heart Disease at Henry Ford Hospital (CSHD), in Henry Ford Hospital, about 250,000 patients are diagnosed with mitral valve diseases annually. Moreover, in Europe, the prevalence of aortic stenosis is 1.75 million. These statistics clearly highlight the need for structural heart treatment devices, thus providing impetus to develop new techniques for repair and replacement of heart defects. In 2007, TAVR procedures were approved in Europe and in 2012 in the U.S. Moreover, around 80,000 patients undergo mitral valve repair or valve replacement surgery each year.

Technological advancements in structural heart devices industry

The upgraded treatments for improving quality of life and increased life expectancy fuel the demand for technologically advanced structural heart devices, such as advanced tissue heart valves useful in structural heart repair and replacement. Further, with the advent of tissue valves used in tissue aortic valve replacement, the quality of life for patients suffering from aortic regurgitation has improved. For instance, in April 2016, launch of St. Jude’s Trifecta valve with Glide Technology (GT), an advanced tissue valve, has made options available for patients in need of aortic valve replacement. Technological innovations result in change in heart-related disorder treatment patterns, lowering the burden of heart disease. Novel tissue valves and mechanical heart valves are widely used to treat structural heart defects with greater longevity. 

Growth in demand for minimally invasive procedures

Structural heart devices and techniques are minimally invasive in nature, and are thus highly preferred over other techniques, such as open heart surgeries. Mitral valve replacement, aortic valve replacement, and prosthetic heart valve replacement procedures are minimally invasive procedures widely used by experts in cardiology to treat structural heart diseases. For instance, as per Center for Structural Heart Disease at Henry Ford Hospital (CSHD), around 80,000 patients undergo mitral valve repair or valve replacement surgery annually. Moreover, innovative developments in structural heart devices and procedures, such as aortic valve replacement valves, left arterial appendage closure devices, and advent of tissue or biological valves, are anticipated to provide promising growth opportunities for the market. 

High cost and risk associated with the treatment procedures

High cost of advanced structural heart devices and risk associated with the procedures are major constraints for market growth. The adoption rate of technologically advanced structural heart devices is low, especially in emerging economies, as these devices are more expensive than their traditional counterparts. For instance, as per Edwards Lifesciences, cost of SAPIEN transcatheter heart valve with the RetroFlex 3 Transfemoral System is $32,500, which is highly expensive for common people. Furthermore, risks associated with these devices are stroke, kidney failure, and gastrointestinal complications, which are observed after mitral valve replacement procedure.

Stringent approval process for structural heart devices

Approval processes for structural heart devices in most of the countries are stringent, as these are highly specialized devices that are introduced in the body. According to the FDA, structural heart devices are classified as class III devices, whereas these devices fall under class IIa (heart valve occluders and tester) and class III (for prosthetic and biological heart valves) category of CE mark classification. In addition, the process is time consuming and requires high investment. According to Advanced Medical Technology Association, it is estimated that about 77% and 80% of the total cost of commercializing a class II and class III medical device, respectively, in the market is spent at FDA-linked approval stages.

STRUCTURAL HEART DEVICES MARKET KEY BENEFITS:

  • The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.

  • It offers a quantitative analysis from 2014 to 2022 to enable stakeholders to capitalize on the prevailing market opportunities.

  • Extensive analysis of the market based on products helps to understand the type of devices used to treat structural heart diseases.

  • Competitive intelligence highlights the business practices followed by leading players across various regions.

  • Comprehensive analysis of all geographical regions helps to determine the prevailing opportunities.

  • Key players and their strategies are analyzed to understand the competitive outlook of the overall market.

  • Extensive analysis is conducted by following key product positioning and monitoring the top contenders within the market framework.

STRUCTURAL HEART DEVICES MARKET KEY SEGMENTS

By Product

  • Repair Devices

    • Annuloplasty Rings

    • Heart Valve Balloons

    • Occluders

  • Replacement Valves

    • Mechanical Heart Valves

    • Tissue Heart Valves

By Indication

  • Atrial Septal Defect (ASD)

  • Ventricular Septal Defect (VSD)

  • Patent Foramen Ovale (PFO)

  • Aortic Valve Stenosis

  • Others 

By Age Group

  • Pediatric

    • Infants (6 months to 12 months)

    • Toddlers (1-2 years)

    • New Born (0-5 months)

    • Preschooler (3-5 years) 

    • School-aged Children (6-12 years) 

    • Adolescent (13-18 years)

  • Adults

    • Young Adults (19-24 years)

    • Adulthood (25-39 years) 

    • Middle-aged Persons (40-59 years) 

    • Older People/Old Age (60-84 years) 

    • Very Old (85+ years)

By Region

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • LAMEA

    • Brazil 

    • South Africa

    • Israel

    • Saudi Arabia

    • Rest of LAMEA

The key companies profiled in the report are Medtronic plc; St. Jude Medical, Inc., Braile Biomedica, Medical Technology Est., Boston Scientific Corporation; Micro Interventional Devices, Inc., Edwards Lifesciences Corporation, LivaNova PLC, JenaValve Technology, Inc., and Cryolife, Inc. Other players operating in this market include Corvia Medical, Inc., CardioKinetix, Inc., Biomerics, LLC, Lepu Medical Technology (Beijing) Co., Ltd., XELTIS BV, and Comed B.V.

 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION

1.1.1. Key benefits for stakeholders
1.1.2. Key market segments

1.2. RESEARCH METHODOLOGY

1.2.1. Secondary research
1.2.2. Primary research
1.2.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.2.2.1. Competitive intelligence of companies and their strategies

3.2.3. Market share analysis, 2015

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. Rise in number of patients suffering from structural heart diseases
3.3.1.2. Increase in risk of cardiovascular diseases owing to growing globalization and industrialization
3.3.1.3. Technological advancements in heart repair and replacement devices
3.3.1.4. Growth in demand for minimally invasive procedures

3.3.2. Restraints

3.3.2.1. High cost and risk associated with the treatment procedures
3.3.2.2. Stringent approval process for structural heart devices

3.3.3. Opportunities

3.3.3.1. Lucrative opportunities in emerging economies

3.4. MITRACLIP MITRAL VALVE REPAIR SYSTEM
3.5. GOVERNMENT REGULATIONS

3.5.1. FDA
3.5.2. Health Canada
3.5.3. CE Mark
3.5.4. Ministry of Health, Labour and Welfare (MHLW)
3.5.5. Therapeutic Goods Administration (TGA)

3.6. REIMBURSEMENT SCENARIO
3.7. CLINICAL TRIALS

Chapter: 4 STRUCTURAL HEART DEVICES MARKET, BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. STRUCTURAL HEART REPAIR DEVICES

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Occluders

4.2.4.1. Market size and forecast

4.2.5. Annuloplasty Rings

4.2.5.1. Market size and forecast

4.2.6. Heart Valve Balloons

4.2.6.1. Market size and forecast

4.3. STRUCTURAL HEART REPLACEMENT DEVICES

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast
4.3.4. Mechanical valves
4.3.5. Market size and forecast
4.3.6. Tissue valves
4.3.7. Market size and forecast

Chapter: 5 STRUCTURAL HEART DEVICES MARKET, BY AGE GROUP

5.1. OVERVIEW

5.1.1. Market Size and Forecast

5.2. PEDIATRIC

5.2.1. Newborns
5.2.2. Infants
5.2.3. Toddlers
5.2.4. Preschoolers
5.2.5. School-aged children
5.2.6. Adolescents
5.2.7. Market size and forecast

5.3. ADULTS

5.3.1. Young adults
5.3.2. Adulthood
5.3.3. Middle-aged persons
5.3.4. Older people/old age
5.3.5. Very old
5.3.6. Market size and forecast

Chapter: 6 STRUCTURAL HEART DEVICES MARKET, BY INDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. ATRIAL SEPTAL DEFECT

6.2.1. Market size and forecast

6.3. PATENT FORAMEN OVALE

6.3.1. Market size and forecast

6.4. VENTRICULAR SEPTAL DEFECT

6.4.1. Market size and forecast

6.5. AORTIC VALVE STENOSIS

6.5.1. Market size and forecast

6.6. OTHER INDICATIONS

6.6.1. Market size and forecast

Chapter: 7 STRUCTURAL HEART DEVICES MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany market size and forecast
7.3.5. France market size and forecast
7.3.6. UK market size and forecast
7.3.7. Italy market size and forecast
7.3.8. Spain market size and forecast
7.3.9. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. Japan market size and forecast
7.4.5. China market size and forecast
7.4.6. India market size and forecast
7.4.7. Australia market size and forecast
7.4.8. Malaysia market size and forecast
7.4.9. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Brazil market size and forecast
7.5.5. South Africa market size and forecast
7.5.6. South Arabia market size and forecast
7.5.7. Rest of LAMEA market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. ST. JUDE MEDICAL, INC.

8.1.1. Overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Business performance
8.1.5. Key strategic moves and developments, 2012-2016

8.2. BRAILE BIOMEDICA

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating product categories

8.3. BOSTON SCIENTIFIC CORPORATION

8.3.1. Overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Business performance
8.3.5. Key strategic moves and developments, 2011-2016

8.4. CRYOLIFE, INC.

8.4.1. Overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Business performance
8.4.5. Key strategic moves and developments, 2011-2016

8.5. EDWARDS LIFESCIENCES CORPORATION

8.5.1. Overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Business performance
8.5.5. Key strategic moves and developments, 2014-2016

8.6. JENAVALVE TECHNOLOGY, INC.

8.6.1. Overview
8.6.2. Company snapshot
8.6.3. Key strategic moves and developments, 2011-2013

8.7. LIVANOVA PLC

8.7.1. Overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Business performance
8.7.5. Key strategic moves and developments, 2016

8.8. MEDICAL TECHNOLOGY EST.

8.8.1. Overview
8.8.2. Company snapshot
8.8.3. Operating business segments

8.9. MEDTRONIC PLC

8.9.1. Overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Business performance
8.9.5. Key strategic moves and developments, 2015-2016

8.10. MICRO INTERVENTIONAL DEVICES, INC.

8.10.1. Overview
8.10.2. Company snapshot
8.10.3. Operating business segments

LIST OF TABLES

TABLE 1. RECALLED PRODUCT
TABLE 2. CPT CODE FOR HEART VALVE TECHNOLOGIES OF EDWARD LIFESCIENCES
TABLE 3. CPT CODE RELATED TO TAVR OF EDWARD LIFESCIENCES
TABLE 4. GLOBAL STRUCTURAL HEART DEVICES MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 5. GLOBAL STRUCTURAL HEART REPAIR DEVICES MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 6. GLOBAL STRUCTURAL HEART REPAIR DEVICES MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 7. OCCLUDERS MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 8. NORTH AMERICA OCCLUDERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 9. EUROPE OCCLUDERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 10. ASIA-PACIFIC OCCLUDERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 11. LAMEA OCCLUDERS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 12. GLOBAL OCCLUDERS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 13. ANNULOPLASTY RINGS MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 14. NORTH AMERICA ANNULOPLASTY RINGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 15. EUROPE ANNULOPLASTY RINGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 16. ASIA-PACIFIC ANNULOPLASTY RINGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 17. LAMEA ANNULOPLASTY RINGS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 18. ANNULOPLASTY RINGS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 19. HEART VALVE BALLOONS MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 20. NORTH AMERICA HEART VALVE BALLOONS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 21. EUROPE HEART VALVE BALLOONS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 22. ASIA-PACIFIC HEART VALVE BALLOONS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 23. LAMEA HEART VALVE BALLOONS MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 24. GLOBAL HEART VALVE BALLOONS MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 25. GLOBAL STRUCTURAL HEART REPLACEMENT DEVICES MARKET, BY TYPE, 2014-2022 ($MILLION)
TABLE 26. GLOBAL STRUCTURAL HEART REPLACEMENT DEVICES MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 27. MECHANICAL HEART VALVES MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 28. NORTH AMERICA MECHANICAL HEART VALVES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 29. EUROPE MECHANICAL HEART VALVES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 30. ASIA-PACIFIC MECHANICAL HEART VALVES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 31. LAMEA MECHANICAL HEART VALVES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 32. GLOBAL MECHANICAL HEART VALVES MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 33. TISSUE HEART VALVES MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 34. NORTH AMERICA TISSUE HEART VALVES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 35. EUROPE TISSUE HEART VALVES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 36. ASIA-PACIFIC TISSUE HEART VALVES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 37. LAMEA TISSUE HEART VALVES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 38. GLOBAL TISSUE HEART VALVES MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 39. GLOBAL STRUCTURAL HEART DEVICES MARKET, BY AGE GROUP, 2014-2022 ($MILLION)
TABLE 40. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR PEDIATRICS, BY AGE GROUP, 2014-2022 ($MILLION)
TABLE 41. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR ADULTS, BY AGE GROUP, 2014-2022 ($MILLION)
TABLE 42. GLOBAL STRUCTURAL HEART DEVICES MARKET, BY INDICATION, 2014-2022
TABLE 43. NORTH AMERICA STRUCTURAL HEART DEVICES MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 44. EUROPE STRUCTURAL HEART DEVICES MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 45. ASIA-PACIFIC STRUCTURAL HEART DEVICES MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 46. LAMEA STRUCTURAL HEART DEVICES MARKET, BY INDICATION, 2014-2022 ($MILLION)
TABLE 47. ATRIAL SEPTAL DEFECT MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 48. PATENT FORAMEN OVALE MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 49. VENTRICULAR SEPTAL DEFECT MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 50. AORTIC VALVE STENOSIS MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 51. STRUCTURAL HEART DEVICES MARKET FOR OTHER INDICATIONS, BY REGION, 2014-2022 ($MILLION)
TABLE 52. STRUCTURAL HEART DEVICES MARKET, BY REGION, 2014-2022 ($MILLION)
TABLE 53. NORTH AMERICA STRUCTURAL HEART DEVICES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 54. EUROPE STRUCTURAL HEART DEVICES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 55. ASIA-PACIFIC STRUCTURAL HEART DEVICES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 56. LAMEA STRUCTURAL HEART DEVICES MARKET, BY COUNTRY, 2014-2022 ($MILLION)
TABLE 57. ST. JUDE MEDICAL: COMPANY SNAPSHOT
TABLE 58. ST. JUDE MEDICAL: PRODUCT CATEGORIES
TABLE 59. BRAILE: COMPANY SNAPSHOT
TABLE 60. BRAILE: PRODUCT CATEGORIES
TABLE 61. BOSTON SCIENTIFIC: COMPANY SNAPSHOT
TABLE 62. BOSTON SCIENTIFIC: OPERATING SEGMENTS
TABLE 63. CRYOLIFE: COMPANY SNAPSHOT
TABLE 64. CRYOLIFE: OPERATING SEGMENTS
TABLE 65. EDWARDS: COMPANY SNAPSHOT
TABLE 66. JENAVALVE: COMPANY SNAPSHOT
TABLE 67. LIVANOVA: COMPANY SNAPSHOT
TABLE 68. LIVANOVA: OPERATING SEGMENTS
TABLE 69. MTE: COMPANY SNAPSHOT
TABLE 70. MTE: PRODUCT CATEGORIES
TABLE 71. MEDTRONIC: COMPANY SNAPSHOT
TABLE 72. MEDTRONIC: BUSINESS SEGMENTS
TABLE 73. MID: COMPANY SNAPSHOT
TABLE 74. MID: PRODUCT CATEGORIES

LIST OF FIGURES

FIGURE 1. STRUCTURAL HEART DEVICES MARKET SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2012-2016 (%)
FIGURE 4. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5. TOP COMPANIES AND THEIR STRATEGIES
FIGURE 6. DETAILED STRUCTURE OF COMPANIES AND TYPE OF STRATEGIES
FIGURE 7. DETAILED STRUCTURE OF COMPANIES AND NATURE OF STRATEGIES
FIGURE 8. MARKET SHARE ANALYSIS, 2015
FIGURE 9. CLINICAL TRIALS IN STRUCTURAL HEART DEVICES MARKET
FIGURE 10. CLINICAL TRIALS FOR STRUCTURAL HEART DEVICES (%)
FIGURE 11. COMPLETED CLINICAL TRIALS FOR STRUCTURAL HEART DEVICES MARKET (%)
FIGURE 12. GLOBAL STRUCTURAL HEART REPAIR DEVICES MARKET FOR OCCLUDERS, 2014-2022 ($MILLION)
FIGURE 13. GLOBAL STRUCTURAL HEART REPAIR DEVICES MARKET FOR ANNULOPLASTY RINGS, 2014-2022 ($MILLION)
FIGURE 14. GLOBAL STRUCTURAL HEART REPAIR DEVICES MARKET FOR HEART VALVE BALLOONS, 2014-2022 ($MILLION)
FIGURE 15. GLOBAL STRUCTURAL HEART REPLACEMENT DEVICES MARKET FOR MECHANICAL VALVES, 2014-2022 ($MILLION)
FIGURE 16. GLOBAL STRUCTURAL HEART REPLACEMENT DEVICES MARKET FOR TISSUE VALVES, 2014-2022 ($MILLION)
FIGURE 17. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR NEWBORNS, 2014-2022 ($MILLION)
FIGURE 18. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR INFANTS, 2014-2022 ($MILLION)
FIGURE 19. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR TODDLERS, 2014-2022 ($MILLION)
FIGURE 20. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR PRESCHOOLERS, 2014-2022 ($MILLION)
FIGURE 21. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR SCHOOL-AGED CHILDREN, 2014-2022 ($MILLION)
FIGURE 22. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR ADOLESCENTS, 2014-2022 ($MILLION)
FIGURE 23. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR YOUNG ADULTS, 2014-2022 ($MILLION)
FIGURE 24. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR ADULTHOOD, 2014-2022 ($MILLION)
FIGURE 25. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR MIDDLE-AGED PERSONS, 2014-2022 ($MILLION)
FIGURE 26. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR OLDER PEOPLE/OLD AGE, 2014-2022 ($MILLION)
FIGURE 27. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR VERY OLD, 2014-2022 ($MILLION)
FIGURE 28. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR ATRIAL SEPTAL DEFECT, 2014-2022 ($MILLION)
FIGURE 29. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR PATENT FORAMEN OVALE, 2014-2022 ($MILLION)
FIGURE 30. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR VENTRICULAR SEPTAL DEFECT, 2014-2022 ($MILLION)
FIGURE 31. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR AORTIC VALVE STENOSIS, 2014-2022 ($MILLION)
FIGURE 32. GLOBAL STRUCTURAL HEART DEVICES MARKET FOR OTHER INDICATIONS, 2014-2022 ($MILLION)
FIGURE 33. TOTAL NUMBER OF TAVR CANDIDATES WORLDWIDE
FIGURE 34. U.S. STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 35. CANADA STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 36. MEXICO STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 37. GERMANY STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 38. FRANCE STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 39. UK STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 40. ITALY STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 41. SPAIN STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 42. REST OF EUROPE STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 43. JAPAN STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 44. CHINA STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 45. INDIA STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 46. AUSTRALIA STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 47. MALAYSIA STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 48. REST OF ASIA-PACIFIC STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 49. BRAZIL STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 50. SOUTH AFRICA STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 51. SOUTH ARABIA STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 52. REST OF LAMEA STRUCTURAL HEART DEVICES MARKET, 2014-2022 ($MILLION)
FIGURE 53. ST. JUDE MEDICAL: FINANCIALS, 2013-2015 ($MILLION)
FIGURE 54. ST JUDE MEDICAL: STRATEGY SHARE, 2012-2016 (%)
FIGURE 55. BOSTON: FINANCIALS, 2013-2015 ($MILLION)
FIGURE 56. BOSTON SCIENTIFIC: STRATEGY SHARE, 2011-2016 (%)
FIGURE 57. CRYOLIFE: FINANCIALS, 2013-2015 ($MILLION)
FIGURE 58. CRYOLIFE: STRATEGY SHARE, 2011-2016 (%)
FIGURE 59. EDWARDS: FINANCIALS, 2013-2015 ($MILLION)
FIGURE 60. EDWARDS: STRATEGY SHARE, 2014-2016 (%)
FIGURE 61. JENAVALVE: STRATEGY SHARE, 2011-2013 (%)
FIGURE 62. LIVANOVA: FINANCIALS, 2013-2015 ($MILLION)
FIGURE 63. LIVANOVA: STRATEGY SHARE, 2016 (%)
FIGURE 64. MEDTRONIC: FINANCIALS, 2014-2016 ($MILLION)
FIGURE 65. MEDTRONIC: STRATEGY SHARE, 2015-2016 (%)

 

Globally, aortic stenosis is the most common type of structural heart defect leading to death. According to WHO, the elderly population of over 60 years of age is estimated to increase from 12% of total population in 2015 to around 22% by 2050. This projected increase in geriatric population, with increased risk of structural heart defects such as aortic stenosis or mitral valve regurgitation, is expected to provide opportunities to medical device companies specialized in treatment of structural heart defects.

Aortic stenosis is caused when the aortic heart valve becomes calcified, leading to complete closure and narrowing of the heart valve. Over time, this disease results in disruption of blood flow from the heart, causing heart weakening, and thus can be treated by transcatheter aortic valve replacement (TAVR).

Transcatheter-based technologies, such as TAVR and transcatheter mitral valve replacement (TMVR), are preferred widely instead of open heart surgeries for treatment of defective aortic and mitral valves, as these technologies provide array of advantages such as cost-effectiveness, quick post-operative recovery period, and less trauma. Companies offering TAVR devices for treatment of aortic stenosis include St. Jude Medical, Inc., which offers Portico Transcatheter Aortic Valve Implantation System and JenaValve Technology GmbH provide JenaValve Prosthesis-23 mm, 25 mm, and 27 mm.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Structural Heart Devices Market- Global Opportunity Analysis and Industry Forecast, 2014-2022

  • Online Only
  • $4176
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo